These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36221373)

  • 1. Cuproptosis-related gene signatures for predicting prognosis of lung adenocarcinoma.
    Ye W; Huang Y; Li X
    Medicine (Baltimore); 2022 Oct; 101(40):e30446. PubMed ID: 36221373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
    Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
    BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
    Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
    Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 7. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
    Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
    Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
    Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
    BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
    Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
    Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
    Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
    Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of lncRNAs related to fatty acid metabolism in lung adenocarcinoma and their correlation with tumor microenvironment based on bioinformatics analysis.
    Pan YQ; Xiao Y; Long T; Liu C; Gao WH; Sun YY; Liu C; Shi YJ; Li S; Shao AZ
    Front Oncol; 2022; 12():1022097. PubMed ID: 36300102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma.
    Wang Z; Yao J; Dong T; Niu X
    J Immunol Res; 2022; 2022():2756611. PubMed ID: 36281357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
    Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
    Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC.
    Wang Y; Xiao X; Li Y
    Sci Rep; 2023 Feb; 13(1):2477. PubMed ID: 36774418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer.
    Xu Q; Liu T; Wang J
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction of Lung Adenocarcinoma Prognosis Model and Drug Sensitivity Analysis Based on Cuproptosis Related Genes].
    Sun J; Zhang H; Liu H; Dong Y; Wang P
    Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):591-604. PubMed ID: 37752539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between copper homeostasis and cuproptosis reveals a lncRNA signature to prognosis prediction, immunotherapy personalization, and agent selection for patients with lung adenocarcinoma.
    Ma C; Gu Z; Ding W; Li F; Yang Y
    Aging (Albany NY); 2023 Nov; 15(22):13504-13541. PubMed ID: 38011277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
    Wang X; Jing H; Li H
    Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.